GU Ventures portfolio company Alzinova ALZ-101 phase 1b data accepted for journal publication

  • GU Ventures portfolio company Alzinova secured acceptance for publication of Phase 1b results for Alzheimer’s vaccine candidate ALZ-101 in peer-reviewed journal Alzheimer’s Research & Therapy.
  • Paper reported favorable safety and tolerability profile, with ALZ-101 generating a targeted immune response in patients with early Alzheimer’s disease.
  • Publication adds external validation as Alzinova prepares next development steps, following FDA clearance in September 2025 to start Phase II trial.
  • FDA granted Fast Track status for ALZ-101 in October 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GU Ventures AB published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.